CLAIMS

1. Use of ALZ-801 in the manufacture of a medicament for the treatment of moderate to severe Alzheimer's disease in an APOE4 homozygous subject, wherein the treatment is to comprise:
    a. administration of 400 mg/day to 600 mg/day of ALZ-801 to the subject for a first period of time until the subject demonstrates a decreased therapeutic response to the first dosage;
    b. administration of a second dosage of 795 mg/day ALZ-801, for a second period of time until the subject demonstrates a decreased therapeutic response to the second dosage; and
    c. administration of third dosage of 1060 mg/day;

    wherein the decreased therapeutic response for a. or b., is demonstrated by one or more of: reduced motor skills, reduced verbalizations, reduced conversation, reduced comprehension, reduced ability to feed oneself, reduced food consumption, reduced mobility, reduced cooperation with caretakers, increased depression, increased agitation, increased aberrant motor behaviors, or increased repetitive movement.

2. The use of claim 1, wherein the decreased therapeutic response is demonstrated over a period of at least two weeks, two to three weeks, at least 6 months, or 6 months to 1 year.

3. The use of claim 1 or 2, wherein the medicament is formulated into a tablet, a capsule, a liquid, an orally dissolving tablet, a sachet, or sprinkles.

4. The use of claim 3, wherein the medicament is formulated into a capsule.